Protocols
9 protocol(s) meet the specified criteria
PI: Anders, Carey
Protocol No.TitleStatus
15-102-14A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician’s Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and CapecitabineOpen
201209135A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast CancerOpen
A221405A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy (POSITIVE)Open
LCCC1419Establishment of Breast Cancer Brain Metastases (BCBM) Registry to Support Research of Molecular Drivers of BCBMOpen
LCCC1639A Non-Randomized, Non-Comparative, Open-Label, Window Trial of Entinostat in Subjects with Borderline ER/PR Positive Breast Cancer and TNBC (Part 1) or Entinostat with or without Exemestane in Subjects with Newly Diagnosed, Stage I-IIIC, Hormone Receptor Positive (HR+) Breast Cancer (Part 2)Open
MM-121-02-02-10SHERBOC: A Double-blind, Placebo-controlled, Phase 2 trial of Seribantumab Plus Fulvestrant in Postmenopausal Women with Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer Whose Disease Progressed After Prior Systemic TherapyOpen
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
ONT-380-206Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)Open
S1416-CIRBPhase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases.Open